---
title: "AKESO grants commercialization rights for Yixinning, receiving a licensing fee of 80 million RMB"
description: "AKESO announced that it has signed an exclusive commercialization rights agreement with JUMPCAN, under which JUMPCAN is authorized to have exclusive commercialization rights for Yixinning (Inusimab In"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/274681417.md"
published_at: "2026-02-03T15:42:37.000Z"
---

# AKESO grants commercialization rights for Yixinning, receiving a licensing fee of 80 million RMB

> AKESO announced that it has signed an exclusive commercialization rights agreement with JUMPCAN, under which JUMPCAN is authorized to have exclusive commercialization rights for Yixinning (Inusimab Injection), which has been independently developed by the company and approved for listing in China (excluding Hong Kong, Macau, and Taiwan). In this cooperation, the company will receive a licensing fee of 80 million RMB, as well as milestone payments of up to 10 million RMB

Akeso (09926.HK) announced that it has signed an exclusive commercialization rights agreement with JUMPCAN (600566.SH), under which JUMPCAN is authorized to have exclusive commercialization rights for Yixinning (Inusimab Injection), which has been independently developed and approved for listing by the company, in China (excluding Hong Kong, Macau, and Taiwan).

In this cooperation, the company will receive a licensing fee of 80 million RMB, as well as milestone payments of up to 10 million RMB

### Related Stocks

- [516820.CN - Ping An CSI Medicine and Medical Device Innovation ETF](https://longbridge.com/en/quote/516820.CN.md)
- [159849.CN - China Merchants CSI Biotechnology Theme ETF](https://longbridge.com/en/quote/159849.CN.md)
- [588250.CN - Penghua SSE STAR Biology and Medicine ETF](https://longbridge.com/en/quote/588250.CN.md)
- [09926.HK - AKESO](https://longbridge.com/en/quote/09926.HK.md)
- [159837.CN - E Fund CSI Biotechnology Theme ETF](https://longbridge.com/en/quote/159837.CN.md)
- [510660.CN - ChinaAMC SSE Health Care ETF Initiating Fund](https://longbridge.com/en/quote/510660.CN.md)
- [560600.CN - Founder Fubon CSI Medicine and Medical Device Innovation ETF](https://longbridge.com/en/quote/560600.CN.md)
- [159859.CN - Tianhong CNI BIOMEDICINE ETF](https://longbridge.com/en/quote/159859.CN.md)
- [512010.CN - E Fund CSI 300 Health Care ETF](https://longbridge.com/en/quote/512010.CN.md)
- [512290.CN - Guotai CSI Bio-medicine ETF](https://longbridge.com/en/quote/512290.CN.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Sino Biopharmaceutical says NMPA approved Benmelstobart injection for marketing | Sino Biopharmaceutical says NMPA approved Benmelstobart injection for marketing | [Link](https://longbridge.com/en/news/276024005.md) |
| SinoMab Wins China IND Nod to Expand SM17 Into Inflammatory Bowel Disease | SinoMab Bioscience Ltd. has received approval from China's National Medical Products Administration for an investigation | [Link](https://longbridge.com/en/news/276765156.md) |
| Sunshine Lake Pharma Wins NMPA Nod to Trial First China-Developed Nipah Virus Antibody | Sunshine Lake Pharma has received approval from China's Center for Drug Evaluation to begin clinical trials for HEC-648  | [Link](https://longbridge.com/en/news/276716153.md) |
| HBM Holdings (SEHK:2142) Valuation After Solstice Oncology Partnership On HBM4003 Rights Outside Greater China | HBM Holdings (SEHK:2142) has entered an exclusive partnership with Solstice Oncology for its clinical asset HBM4003 outs | [Link](https://longbridge.com/en/news/276700073.md) |
| Palumbo Wealth Management LLC Buys New Stake in ProShares Ultra Nasdaq Biotechnology $BIB | Palumbo Wealth Management LLC acquired a new stake in ProShares Ultra Nasdaq Biotechnology (NASDAQ:BIB) during the third | [Link](https://longbridge.com/en/news/276735169.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.